Zhongqi Capital
VC Fund
Beijing, China
Zhongqi Capital is an investment firm that offers a private equity investment management platform.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Zhongqi Capital invests in
Stages Zhongqi Capital invests in
Countries Zhongqi Capital invests in
Round sizes
Round size
- Series A
- $35M–$59M
Investment Focus
Industry
- Manufacturing 7 (32%)
- Electronics 5 (23%)
- Biotechnology 5 (23%)
- Advanced Materials 5 (23%)
- Industrial 4 (18%)
Stage
- Series A 8 (36%)
- Seed 5 (23%)
- Private Equity 3 (14%)
- Series B 2 (9%)
- Series D 2 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Hannto Technology designs, develops and produces intelligent hardware. | Private Equity / Oct 28, 2026 | ||
| Langsilicon Technology is an electronic component R&D firm that specializes in the design, development, and sales of silicon-based passive components (capacitors, inductors, and resistors). | $29.9M / Seed / Sep 23, 2026 | ||
| Inno Pharmaceutical Technology specializes in research on the pathogenesis of atherosclerosis. The company focuses on the development of targeted nanoliposomes, targeting molecules with independent intellectual property rights, and currently focuses on the plaque reversal treatment of atherosclerosis. | $119.2M / Series D / Sep 09, 2026 | ||
| SiranBio is a biotechnology that develops innovative siRNA drugs. | $59.5M / Series A / Aug 20, 2026 | ||
|
Weikai High-Tech
|
Sifang Weikai High-Tech operates an intelligent Industry 4.0 production base, and its products are widely used in autos, motorbikes, rail transit, and construction machines. | Series A / Aug 03, 2026 | |
|
Sifang Weikai
|
Sifang Weikai focuses on high-end industrial decorative coatings and functional materials for high-end equipment. | Series A / Aug 02, 2026 | |
Topwell Biotech
|
Topwell Biotech is a biotechnology company offering research and development of synthetic biology technologies and biodegradable materials. | Series A / May 21, 2026 | |
| Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $145.4M / Series E / Apr 03, 2026 | ||
|
Yonggeng Technology
|
Yonggeng Technology focuses on the development and industrial application of high-end photolithography media materials. | Series A / Nov 04, 2025 | |
| Feature-Tec is a filtration and separation technology that specializes in R&D, design, manufacturing, and verification. | Private Equity / Nov 03, 2025 | ||
| See all 22 investments → | |||
Co-Investors
BioVenture
2 deals together
Guotai Junan Innovation Investment
2 deals together
Airport Venture Capital
1 deal together
AstraZeneca CICC Medical Industry Fund
1 deal together
Gaorong Capital
1 deal together
Beijing Advanced Manufacturing and Intelligent Equipment Industry Investment Fund
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Zhongqi Capital invest in?
Zhongqi Capital invests primarily in Manufacturing, Electronics and Biotechnology startups, most often at Series A and Seed stage. Most of the 22 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Zhongqi Capital invest in?
Zhongqi Capital typically joins rounds of $35M–$59M at Series A. These are whole funding-round sizes, not Zhongqi Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Zhongqi Capital took part in.
When did Zhongqi Capital last invest?
The most recent investment recorded for Zhongqi Capital closed in Oct 2026. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
